Supporting this notion, the insulin-sensitizing drug rosiglitazone can have direct, protective, effects on podocyte insulin responses (74) and similar, systemic, insulin-sensitizing drugs can protect against albuminuria, in both experimental diabetic nephropathy models and clinical studies (79–81), suggesting that this beneficial effect may be in part mediated by protecting podocyte insulin signaling. Here, INS is linked to diabetic kidney disease.